Literatur
-
1
Tassopoulos N C, Volpes R, Pastore G. et al .
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Hepatology.
1999;
29
889-896 (Ib)
-
2
Teuber G, Lohr H F, Kallinowski B. et al .
Retrospektive Kohortenstudie zur Lamivudintherapie bei Patienten mit chronischer Hepatitis B.
Dtsch Med Wochenschr.
2001;
126
97-102 (III)
-
3
Hadziyannis S J, Papatheodoridis G V, Vassilopoulos D.
Treatment of HBeAg-negative chronic hepatitis B.
Semin Liver Dis.
2003;
23
81-88 (Übersicht)
-
4
Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al .
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
N Engl J Med.
2003;
348
800-807 (Ib)
-
5
Lok A S, Heathcote E J, Hoofnagle J H.
Management of hepatitis B: 2000 - summary of a workshop.
Gastroenterology.
2001;
120
1828-1853 (Übersicht)
-
6
Perrillo R, Tamburro C, Regenstein F. et al .
Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.
Gastroenterology.
1995;
109
908-916 (IIb)
-
7
Nair S, Perrillo R P.
Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia.
Hepatology.
2001;
34
1021-1026 (IIb)
-
8
Hoofnagle J H, Di Bisceglie A M, Waggoner J G. et al .
Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.
Gastroenterology.
1993;
104
1116-1121 (III)
-
9
Fontana R J, Hann H W, Perrillo R P. et al .
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.
Gastroenterology.
2002;
123
719-727 (IIa)
-
10
Yao F Y, Bass N M.
Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.
J Hepatol.
2000;
33
301-307 (IIb)
-
11
Yao F Y, Terrault N A, Freise C. et al .
Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
Hepatology.
2001;
34
411-416 (IIb)
-
12
Kapoor D, Guptan R C, Wakil S M. et al .
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
J Hepatol.
2000;
33
308-312 (IIb)
-
13
Villeneuve J P, Condreay L D, Willems B. et al .
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
J. Hepatology.
2000;
31
207-210 (IIb)
-
14
Perrillo R P, Wright T, Rakela J. et al .
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.
Hepatology.
2001;
33
424-432 (IIb)
-
15
Roche B, Samuel D.
Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results.
J Hepatol.
2003;
39 (Suppl. I)
181-189 (Übersicht)
-
16
Steinmuller T, Seehofer D, Rayes N. et al .
Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.
Hepatology.
2002;
35
1528-1535 (III)
-
17
Schiff E R, Lai C L, Neuhaus P. et al .
Hepatology.
2002;
36
371A (IIb)
-
18
Lok A S.
Prevention of recurrent hepatitis B post-liver transplantation.
Liver Transpl.
2002;
8
67-73 (Übersicht)
-
19
Bienzle U, Gunther M, Neuhaus R. et al .
Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results.
Liver Transpl.
2002;
8
562-564 (III)
-
20
Berenguer M, Wright T.
Treatment of recurrence of hepatitis B in transplant patients.
J Hepatol.
2003;
39 (Suppl. I)
190-193 (Übersicht)
-
21
Bock C T, Tillmann H L, Torresi J. et al .
Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
Gastroenterology.
2002;
122
264-273 (III)
-
22
Kruger M, Tillmann H L, Trautwein C. et al .
Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.
Liver Transpl Surg.
1996;
2
253-262 (IIb)
-
23
Tillmann H L, Trautwein C, Bock C T. et al .
Lamivudine transiently reduces viral load and improves liver function in liver transplant recipients with fibrosing cholestatic hepatitis.
Am J Gastroenterol.
2002;
97
777-778 (IIb)
-
24
Kliem V, Ringe B, Holhorst K. et al .
Kidney transplantation in hepatitis B surface antigen carriers.
Clin Investig.
1994;
72
1000-1006 (III)
-
25
Rao K V, Kasiske B L, Anderson W R.
Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients.
Transplantation.
1991;
51
391-396 (III)
-
26
Aroldi A, Tarantino A, Montagnino G. et al .
Renal transplant recipients and chronic liver disease: statistical evaluation of predisposing factors.
Nephron.
1992;
61
290-292 (III)
-
27
Fairley C K, Mijch A, Gust I D. et al .
The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive.
Transplantation.
1991;
52
497-500 (III)
-
28
Tillmann H L, Wedemeyer H, Manns M P.
Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation.
J. Hepatol.
2003;
39 (Suppl. I)
206-211 (Übersicht)
-
29
Al F araidy K, Yoshida E M, Davis J E. et al .
Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine.
Transplantation.
1997;
64
926-928 (III)
-
30
Chan T M, Wu P C, Li F K. et al .
Treatment of fibrosing cholestatic hepatitis with lamivudine.
Gastroenterology.
1998;
115
177-181 (III)
-
31
Jung S, Lee H C, Han J M. et al .
Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine.
J Gastroenterol Hepatol.
2002;
17
345-350 (III)
-
32
Natov S N, Pereira B J.
Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus).
Transpl Infect Dis.
2002;
4
117-123 (Übersicht)
-
33
Prieto M, Gomez M D, Berenguer M. et al .
De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Liver Transpl.
2001;
7
51-58 (III)
-
34
Dodson S F, Issa S, Araya V. et al .
Infectivity of hepatic allografts with antibodies to hepatitis B virus.
Transplantation.
1997;
64
1582-1584 (III)
-
35
Dickson R C, Everhart J E, Lake J R. et al .
Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Gastroenterology.
1997;
113
1668-1674 (III)
-
36
Douglas D D, Rakela J, Wright T L. et al .
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient.
Liver Transpl Surg.
1997;
3
105-111 (III)
-
37
Lok A S, Liang R H, Chiu E K. et al .
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.
Gastroenterology.
1991;
100
182-188 (III)
-
38
Nakamura Y, Motokura T, Fujita A. et al .
Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.
Cancer.
1996;
78
2210-2215 (III)
-
39
Kumagai K, Takagi T, Nakamura S. et al .
Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.
Ann Oncol.
1997;
8 (Suppl. 1)
107-109 (III)
-
40
Markovic S, Drozina G, Vovk M. et al .
Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.
Hepatogastroenterology.
1999;
46
2925-2930 (III)
-
41
Yeo W, Chan P K, Zhong S. et al .
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
J Med Virol.
2000;
62
299-307 (III)
-
42
Lau G K, Liang R, Chiu E K. et al .
Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.
Bone Marrow Transplant.
1997;
19
795-799 (III)
-
43
Chen P M, Chiou T J, Fan F S. et al .
Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation.
Transplantation.
1999;
67
1425-1433 (III)
-
44
Dhedin N, Douvin C, Kuentz M. et al .
Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.
Transplantation.
1998;
66
616-619 (III)
-
45
Romand F, Michallet M, Pichoud C. et al .
Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B.
Gastroenterol Clin Biol.
1999;
23
770-774 (III)
-
46
Iwai K, Tashima M, Itoh M. et al .
Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period.
Bone Marrow Transplant.
2000;
25
105-108 (III)
-
47
Cheng A L.
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Blood.
1996;
87
1202 (IIb)
-
48
Yeo W, Steinberg J L, Tam J S. et al .
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
J Med Virol.
1999;
59
263-269 (IIb)
-
49
ter B org F, Smorenburg S, de Man R A. et al .
Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.
Dig Dis Sci.
1998;
43
2267-2270 (IIb)
-
50
Farrell G C.
Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation.
J Gastroenterol Hepatol.
1999;
14
741-744 (Editorial)
-
51
Ahmed A, Keeffe E B.
Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
Am J Gastroenterol.
1999;
94
249-251 (III)
-
52
Clark F L, Drummond M W, Chambers S. et al .
Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.
Ann Oncol.
1998;
9
385-387 (III)
-
53
Lee W C, Wu M J, Cheng C H. et al .
Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
Am J Kidney Dis.
2001;
38
1074-1081 (IIa)
-
54
Silvestri F, Ermacora A, Sperotto A. et al .
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation.
Br J Haematol.
2000;
108
394-396 (III)
-
55
Rossi G, Pelizzari A, Motta M. et al .
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Br J Haematol.
2001;
115
58-62 (III)
-
56
Endo T, Sakai T, Fujimoto K. et al .
A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Bone Marrow Transplant.
2001;
27
433-436 (III)
-
57
Lau G K, He M L, Fong D Y. et al .
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
Hepatology.
2002;
36
702-709 (III)
-
58
Munster T, Weis N M, Krogsgaard K.
Polyarteritis nodosa and hepatitis B infection treated with lamivudine.
Ugeskr Laeger.
2002;
164
342-343 (III)
-
59
Gupta S, Piraka C, Jaffe M.
Lamivudine in the treatment of polyarteritis nodosa associated with acute hepatitis B.
N Engl J Med.
2001;
344
1645-1646 (III)
-
60
ter B org F, Smorenburg S, de Man R A. et al .
Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.
Dig Dis Sci.
1998;
43
2267-2270 (III)
-
61
Clark F L, Drummond M W, Chambers S. et al .
Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.
Ann Oncol.
1998;
9
385-387 (III)
-
62
Kazim S N, Wakil S M, Khan L A. et al .
Vertical transmission of hepatitis B virus despite maternal lamivudine therapy.
Lancet.
2002;
359
1488-1489 (III)
-
63
Perrillo R, Schiff E, Yoshida E. et al .
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Hepatology.
2000;
32
129-134 (III)
-
64
Peters M, Hann H W, Martin P. et al .
Hepatology.
2002;
36
374A (Ib)
Prof. Dr. med. H. E. Blum
Albert-Ludwigs-Universität, Innere Abteilung II
Hugstetter-Str. 55
79106 Freiburg
Email: heblum@ukl.uni-freiburg.de
